Goldman Sachs Group Inc Tango Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $706 Billion
  • Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 108,179 shares of TNGX stock, worth $945,484. This represents 0.0% of its overall portfolio holdings.

Number of Shares
108,179
Previous 172,433 37.26%
Holding current value
$945,484
Previous $236,000 134.32%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$1.1 - $5.47 $70,679 - $351,469
-64,254 Reduced 37.26%
108,179 $553,000
Q1 2025

May 09, 2025
SELL
$1.37 - $3.47 $430,803 - $1.09 Million
-314,455 Reduced 64.58%
172,433 $236,000
Q4 2024

Feb 11, 2025
SELL
$2.79 - $7.46 $157,939 - $422,303
-56,609 Reduced 10.42%
486,888 $1.5 Million
Q3 2024

Nov 14, 2024
SELL
$7.36 - $11.93 $525,658 - $852,052
-71,421 Reduced 11.61%
543,497 $4.18 Million
Q2 2024

Aug 13, 2024
BUY
$6.66 - $10.15 $8,098 - $12,342
1,216 Added 0.2%
614,918 $5.28 Million
Q1 2024

May 15, 2024
BUY
$7.51 - $12.88 $1.24 Million - $2.12 Million
164,487 Added 36.62%
613,702 $4.87 Million
Q4 2023

Feb 13, 2024
BUY
$6.52 - $12.01 $2.18 Million - $4.02 Million
334,355 Added 291.1%
449,215 $4.45 Million
Q3 2023

May 14, 2024
SELL
$2.93 - $11.26 $979,660 - $3.76 Million
-334,355 Reduced 74.43%
114,860 $1.29 Million
Q3 2023

Nov 14, 2023
BUY
$2.93 - $11.26 $71,178 - $273,539
24,293 Added 26.82%
114,860 $1.29 Million
Q2 2023

May 14, 2024
BUY
$2.67 - $4.7 $25,119 - $44,217
9,408 Added 11.59%
90,567 $300,000
Q2 2023

Aug 14, 2023
BUY
$2.67 - $4.7 $25,119 - $44,217
9,408 Added 11.59%
90,567 $300,000
Q1 2023

May 14, 2024
BUY
$3.76 - $8.06 $41,830 - $89,667
11,125 Added 15.89%
81,159 $320,000
Q1 2023

May 11, 2023
BUY
$3.76 - $8.06 $41,830 - $89,667
11,125 Added 15.89%
81,159 $320,000
Q4 2022

May 14, 2024
SELL
$3.41 - $8.29 $697,522 - $1.7 Million
-204,552 Reduced 74.49%
70,034 $507,000
Q4 2022

Feb 13, 2023
SELL
$3.41 - $8.29 $697,522 - $1.7 Million
-204,552 Reduced 74.49%
70,034 $507,000
Q3 2022

May 14, 2024
BUY
$3.25 - $5.46 $631,120 - $1.06 Million
194,191 Added 241.55%
274,586 $994,000
Q3 2022

Nov 10, 2022
BUY
$3.25 - $5.46 $631,120 - $1.06 Million
194,191 Added 241.55%
274,586 $994,000
Q2 2022

May 14, 2024
SELL
$3.86 - $8.01 $1.42 Million - $2.95 Million
-368,820 Reduced 82.1%
80,395 $364,000
Q2 2022

Aug 15, 2022
SELL
$3.86 - $8.01 $82,569 - $171,341
-21,391 Reduced 21.02%
80,395 $364,000
Q1 2022

May 16, 2022
BUY
$7.01 - $10.94 $134,451 - $209,829
19,180 Added 23.22%
101,786 $772,000
Q4 2021

Feb 14, 2022
BUY
$9.55 - $14.29 $788,887 - $1.18 Million
82,606 New
82,606 $904,000

Others Institutions Holding TNGX

# of Institutions
124
Shares Held
117M
Call Options Held
245K
Put Options Held
18.9K
View Full List

About Tango Therapeutics, Inc.

TNGX Quotes by TradingView
  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $770M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email